Notable Price Action: Is Buying Nektar Therapeutics Here a Winning Strategy?

Notable Price Action: Is Buying Nektar Therapeutics Here a Winning Strategy?

The stock of Nektar Therapeutics (NASDAQ:NKTR) is a huge mover today! About 2.00M shares traded hands. Nektar Therapeutics (NASDAQ:NKTR) has declined 16.90% since April 4, 2016 and is downtrending. It has underperformed by 17.99% the S&P500.
The move comes after 5 months positive chart setup for the $1.89B company. It was reported on Nov, 4 by Barchart.com. We have $18.02 PT which if reached, will make NASDAQ:NKTR worth $793.80 million more.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Out of 2 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nektar Therapeutics has been the topic of 4 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by TheStreet on Wednesday, August 26. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Overweight” rating by Piper Jaffray on Thursday, January 7. The company was maintained on Monday, September 21 by Roth Capital.

According to Zacks Investment Research, “Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company’s wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.”

Insitutional Activity: The institutional sentiment increased to 1.14 in Q2 2016. Its up 0.05, from 1.09 in 2016Q1. The ratio increased, as 16 funds sold all Nektar Therapeutics shares owned while 56 reduced positions. 22 funds bought stakes while 60 increased positions. They now own 131.60 million shares or 3.23% less from 135.99 million shares in 2016Q1.
The Delaware-based Blackrock Advsr Ltd Liability Co has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Tiaa Cref Mgmt Ltd Liability Company holds 0.01% or 570,890 shares in its portfolio. Great West Life Assurance Can has 0% invested in the company for 14,594 shares. Texas Permanent School Fund, a Texas-based fund reported 104,189 shares. Marshall Wace Limited Liability Partnership has invested 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Tang Capital Management Ltd accumulated 260,000 shares or 1.65% of the stock. Goldman Sachs Inc holds 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 394,624 shares. Peak6 Invests L P accumulated 15,485 shares or 0% of the stock. Rothschild Asset Mngmt has invested 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Moreover, Harvey Cap Mgmt has 3.73% invested in Nektar Therapeutics (NASDAQ:NKTR) for 523,100 shares. Comerica National Bank & Trust last reported 136,538 shares in the company. Proshare Limited Liability Co last reported 120,322 shares in the company. Arizona State Retirement Systems holds 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 70,745 shares. Teachers Advsr Inc holds 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 302,617 shares. Advisory Svcs Network Ltd Liability has 0% invested in the company for 400 shares.

Insider Transactions: Since May 16, 2016, the stock had 1 buying transaction, and 23 selling transactions for $5.73 million net activity. 339 shares were sold by Doberstein Stephen K, worth $4,604 on Monday, May 16. 9,000 shares were sold by Lingnau Lutz, worth $171,540. Shares for $69,731 were sold by Thomsen Jillian B. on Tuesday, August 16. Gergel Ivan P. sold $29,589 worth of Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, August 16. The insider CHESS ROBERT sold $77,500. Shares for $11,339 were sold by Hora Maninder. Nicholson John sold $11,624 worth of stock.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar Therapeutics’ (NKTR) CEO Howard Robin on Q3 2016 Results – Earnings …” on November 04, 2016, also Cnbc.com with their article: “Nektar Therapeutics shares fall on secondary stock offering” published on October 19, 2016, Prnewswire.com published: “Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for …” on October 28, 2016. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Reuters.com and their article: “BRIEF-Nektar Therapeutics reports financial results for Q3” published on November 03, 2016 as well as Forbes.com‘s news article titled: “Nektar Therapeutics Becomes Oversold (NKTR)” with publication date: October 18, 2016.

NKTR Company Profile

Nektar Therapeutics, incorporated on June 3, 1998, is a clinical-stage biopharmaceutical company. The Firm is developing a pipeline of drug candidates that utilizes its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of molecular entities that targets known mechanisms of action. The Company’s pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs, peptides and other biologic drug candidates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment